Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Michela Ansuinelli, Haesook T. Kim, Carol G. Reynolds, Francesco Malfona, Shuntaro Ikegawa, Rakuyo Tamada, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, John Koreth, Vincent T. Ho, Corey S. Cutler, Joseph H. Antin, Leslie Kean, Robert J. Soiffer, Jerome Ritz

Blood (2024) 144 (Supplement 1): 1041.

https://doi.org/10.1182/blood-2024-201835

Published: 2024

Journal Articles

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Blood (2024) 144 (Supplement 1): 379.

https://doi.org/10.1182/blood-2024-200128

Published: 2024

Journal Articles

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Roman M. Shapiro, Haesook T. Kim, William H Terral, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Joseph H. Antin, Katie Maurer, Catherine J. Wu, Robert Zeiser, Jerome Ritz, Robert J. Soiffer, Sarah Nikiforow, John Koreth

Blood (2024) 144 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2024-194102

Published: 2024

Journal Articles

A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies

Elena Maroto Martin, Yingjie Zhao, Sara Mangesh Kolhatkar, Roberto Garcia-Vicente, Mubin Tarannum, Mehmet K. Samur, Mariateresa Fulciniti, Rizwan Romee, Jianzhu Chen, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2024-208607

Published: 2024

Journal Articles

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Jessica S. Little, Kyle Hebert, Donna S. Neuberg, Sarah Nikiforow, Mahasweta Gooptu, Roman M. Shapiro, John Koreth, Joseph H. Antin, Corey S. Cutler, Robert J. Soiffer, Jerome Ritz, Rizwan Romee, Vincent T. Ho, Nicolas C Issa, Lindsey R. Baden, Remy Dulery, Susan E Prockop

Blood (2024) 144 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2024-205169

Published: 2024

Journal Articles

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Blood (2024) 144 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2024-209087

Published: 2024

Journal Articles

Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2024-205070

Published: 2024

Journal Articles

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Blood (2024) 144 (Supplement 1): 3500.

https://doi.org/10.1182/blood-2024-199776

Published: 2024

Journal Articles

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Jieun Jang, Mila Stanojevic, Sara Piccinelli, Michal Sheffer, Grace Caroline Birch, Roman M. Shapiro, Maximilian Stahl, John Koreth, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Mubin Tarannum, Rizwan Romee

Blood (2024) 144 (Supplement 1): 917.

https://doi.org/10.1182/blood-2024-204369

Published: 2024

Journal Articles

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

H. Moses Murdock, Haesook T. Kim, Katie Maurer, Amar H. Kelkar, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Corey S. Cutler, John Koreth, Jerome Ritz, Joseph H. Antin, Vincent T. Ho, Sarah Nikiforow, Catherine J. Wu, Robert J. Soiffer

Blood (2024) 144 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2024-204343

Published: 2024

Journal Articles

One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Fuguo Liu, Mubin Tarannum, Yingjie Zhao, Yiming J Zhang, James Dongjoo Ham, Kewen Lei, Yuhao Qiang, Xingyu Deng, Maily Nguyen, Dinh Khanhlinh, Shaobo Yang, Alaa Kassim Ali, Grace Caroline Birch, Yuwen Yin, Junru Cui, Fangfeng Yuan, Jerome Ritz, Jianzhu Chen, Rizwan Romee

Blood (2024) 144 (Supplement 1): 915.

https://doi.org/10.1182/blood-2024-198167

Published: 2024

Journal Articles

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Jooeun Bae, Shuichi Kitayama, Zach Herbert, Laurence Daheron, Keiji Kurata, Derin B. Keskin, Kenneth Livak, Shuqiang Li, Mubin Tarannum, Rizwan Romee, Mehmet Samur, Nikhil C. Munshi, Shin Kaneko, Jerome Ritz, Kenneth C. Anderson

Blood (2024) 143 (10): 895–911.

https://doi.org/10.1182/blood.2023020528

Published: 2024

Includes: Supplemental data

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 772.

https://doi.org/10.1182/blood-2023-190832

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Blood (2023) 142 (Supplement 1): 6850.

https://doi.org/10.1182/blood-2023-178362

Published: 2023

Journal Articles

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Blood (2022) 140 (Supplement 1): 8343–8344.

https://doi.org/10.1182/blood-2022-167535

Published: 2022

Journal Articles

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4204–4206.

https://doi.org/10.1182/blood-2022-164811

Published: 2022

Journal Articles

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Blood (2022) 140 (Supplement 1): 917–919.

https://doi.org/10.1182/blood-2022-157611

Published: 2022

NARROW

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only